In 2003, malignant pleural mesothelioma (MPM) was a disease with a poor prognosis and
most patients succumbed to their disease within a year of diagnosis. Many phase II trials of …

BACKGROUND Pemetrexed‐cisplatin chemotherapy is the standard of care in the first‐line
treatment of unresectable malignant pleural mesothelioma (MPM). Second‐line cytotoxic …

Opinion statement Unresectable or relapsed malignant pleural mesothelioma (MPM) has
dismal prognosis. First-line combination therapy with pemetrexed and a platinum analog …

Purpose Pemetrexed and gemcitabine have single-agent activity in malignant pleural
mesothelioma (MPM). The combination of pemetrexed/gemcitabine has not previously been …

Background: The current standard first-line chemotherapy for malignant pleural
mesothelioma (MPM) is pemetrexed and cisplatin. However, other regimens, with or without …

TPS8574 Background: Median overall survival (OS) is~ 1 year with P/C, the standard front-
line treatment for patients (pts) with unresectable MPM; additional improvement is needed …

e20030 Background: Cetuximab is a chimeric monoclonal antibody targeting the epidermal
growth factor receptor (EGFR). Previous studies suggested that cetuximab enhances …

MALIGNANT PLEURAL mesothelioma (MPM) is an un-common malignancy with an
estimated incidence of 2,000 to 3,000 cases annually in the United States. However, the …

Background Pleural mesothelioma usually presents at an advanced, incurable stage.
Chemotherapy with platinum–pemetrexed is a standard treatment. We hypothesised that the …

Objectives This article aims to review the evidence from recent clinical trials in
mesothelioma, and to provide an overview of relevant clinical trials that are currently in …